Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics Limited has announced the quotation of 20 million ordinary fully paid securities on the Australian Securities Exchange (ASX), which forms part of a previously announced transaction. This move is expected to broaden the company’s capital base, potentially enhancing its financial capacity to advance its cancer treatment therapies, thereby potentially impacting its market position and stakeholder interests positively.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited operates in the biotechnology industry, focusing on the development of innovative cell therapies. The company primarily specializes in designing and advancing CAR T cell therapies aimed at treating cancer, positioning itself within a niche but growing segment of the healthcare market.
Average Trading Volume: 2,633,915
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$11.03M
For an in-depth examination of CHM stock, go to TipRanks’ Stock Analysis page.
